Literature DB >> 534583

Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure.

J Mehta, M Iacona, C J Pepine, C R Conti.   

Abstract

The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients. Both oral agents were well tolerated and appeared to have beneficial haemodynamic effects. Prazosin and hydralazine produced similar increases in cardiac output associated with a similar decrease in systemic vascular resistance. Prazosin and hydralazine produced similar increases in cardiac output associated with a similar decrease in systemic vascular resistance. Prazosin resulted in a more significant decline in left ventricular filling pressure and pulmonary vascular resistance than did hydralazine. Haemodynamic alterations induced by prazosin were similar to those induced by nitroprusside, which suggests a relatively balanced reduction of preload and afterload. With hydralazine, the increase in cardiac output without change in left ventricular filling pressure or pulmonary vascular resistance suggests minimal effect on preload but significant reduction in afterload.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 534583      PMCID: PMC482219          DOI: 10.1136/hrt.42.6.664

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  24 in total

1.  Afterload as a primary determinat of ventricular performance.

Authors:  E H SONNENBLICK; S E DOWNING
Journal:  Am J Physiol       Date:  1963-04

2.  Direct and reflex cardiostimulating effects of hydralazine.

Authors:  I Khatri; N Uemura; A Notargiacomo; E D Freis
Journal:  Am J Cardiol       Date:  1977-07       Impact factor: 2.778

3.  Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodynamics and echocardiography.

Authors:  N A Awan; R R Miller; A N DeMaria; K S Maxwell; A Neumann; D T Mason
Journal:  Circulation       Date:  1977-09       Impact factor: 29.690

4.  Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin.

Authors:  R R Miller; N A Awan; K S Maxwell; D T Mason
Journal:  N Engl J Med       Date:  1977-08-11       Impact factor: 91.245

Review 5.  Drug therapy. Prazosin.

Authors:  J Koch-Weser; R M Graham; W A Pettinger
Journal:  N Engl J Med       Date:  1979-02-01       Impact factor: 91.245

Review 6.  The role of vasodilator therapy in heart failure.

Authors:  K Chatterjee; W W Parmley
Journal:  Prog Cardiovasc Dis       Date:  1977 Jan-Feb       Impact factor: 8.194

7.  Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside.

Authors:  G L Pierpont; J N Cohn; J A Franciosa
Journal:  Chest       Date:  1978-01       Impact factor: 9.410

8.  Comparative hemodynamic effects of intravenous nitroprusside and oral prazosin in refractory heart failure.

Authors:  J Mehta; M Iacona; R L Feldman; C J Pepine; C R Conti
Journal:  Am J Cardiol       Date:  1978-05-01       Impact factor: 2.778

9.  Haemodynamic effects of hydrallazine and of hydrallazine plus glyceryl trinitrate paste in heart failure.

Authors:  J Mehta; C J Pepine; C R Conti
Journal:  Br Heart J       Date:  1978-08

10.  Aortic input impedance in heart failure.

Authors:  C J Pepine; W W Nichols; C R Conti
Journal:  Circulation       Date:  1978-09       Impact factor: 29.690

View more
  2 in total

1.  Acute and chronic haemodynamic effects of prazosin in left ventricular failure.

Authors:  L Stein; P R Foster; A W Friedman; J Statza; P L McHenry
Journal:  Br Heart J       Date:  1981-02

Review 2.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.